John Libbey Eurotext

Médecine thérapeutique

Revue pharmacologique des antitussifs et leur place dans le traitement de la bronchite aiguë virale Volume 23, numéro 1, Janvier-Février 2017

  • [1] Morrell D.C. Symptom interpretation in general practice. J R Coll Gen Pract. 1972;22:297e-309.
  • [2] Gonzales R., Sander A.M. Uncomplicated acute bronchitis. Ann Intern Med. 2000;133:981-991.
  • [3] Wenzel R.P., Fowler A.A. 3rd. Clinical practice. Acute bronchitis. N Engl J Med. 2006;355:2125.
  • [4] Schroeder K., Fahey T. Should we advise parents to administer over the counter cough medicines for acute cough? Systematic review of randomised controlled trials. Arch Dis Child. 2002;86:170-175.
  • [5] BolserF D.C. Cough suppressant. Pharmacologic protussive therapy. Chest. 2006;129:238S-249S.
  • [6] Peter V. Dicpinigaitis. Currently available antitussives. Pulm Pharmacol Ther. 2009;22:148-151.
  • [7] McDonald J., Lambert D.G. Opioid receptors. Continuing education in anaesthesia. Crit Care Pain. 2005;5:22-25.
  • [8] Gibson P.G., Ryan N.M. Cough pharmacotherapy: current and future status. Expert Opin Pharmacother. 2011;12:P11-09653.
  • [9] Crews KR, Gaedigk A, Dunnenberger HM, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy : 2014 update. Clin Pharmacol Ther 2014; 95: 376-82.
  • [10] Codeine containing medicinal products for the treatment of cough and/or cold in paediatric patients. Procedure number : EMEA/H/A-31/1394. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Codeine_cough_or_cold_in_children/Position_provided_by_CMDh/WC500186159.pdf, janvier 2017.
  • [11] Kelly D.A. Comparative clinical test of pholcodine with codeine as control. Northwest Med. 1963;62:871-874.
  • [12] Jaffe G., Grimshaw J.J. Randomized single-blind trial in general practice comparing the efficacy and palatability of two cough linctus preparations, ‘Pholcodix’ and ‘Actifed’ compound, in children with acute cough. Curr Med Res Opin. 1983;8:594-599.
  • [13] De Blasio F., Dicpinigaitis P.V., Rubin B.K., De Danieli G., Lanata L., Zanasi A. An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome. Cough. 2012;8:1.
  • [14] Taylor J.A., Novack A.H., Almquist J.R., Rogers J.E. Efficacy of cough suppressants in children. J Pediatr. 1993;122:799-802.
  • [15] Smith S.M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2012;8:CD001831.
  • [16] Eccles R., Morris S., Jawad M. Lack of effect of codeine in the treatment of cough associated with acute upper respiratory tract infection. J Clin Pharm Ther. 1992;17:175-180.
  • [17] Freestone C., Eccles R. Assessment of the antitussive efficacy of codeine in cough associated with common cold. J Pharm Pharmacol. 1997;49:1045-1049.
  • [18] Courrier mis en ligne le 10 mars 2016 sur www.ansm.sante.fr/.
  • [19] Heffron C.E. Preliminary evaluation of pholcodine, a new antitussive agent. J New Drugs. 1961;1:217-222.
  • [20] Equinozzi R., Robuschi M. Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough: a randomized, double-blind, multicenter study. Treat Respir Med. 2006;5:509-513.
  • [21] European Medicine Agency. Assessment report for Pholcodine containing medicinal products. Procedure number: EMEA/H/A-31/1292. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Pholcodine_31/WC500124716.pdf, janvier 2017.
  • [22] European Medicine Agency. Annexe II. Conclusions scientifiques et motifs du maintien des autorisations de mise sur le marché présentés par l’EMA. http://www.ema.europa.eu/docs/fr_FR/document_library/Referrals_document/cyproterone_ethinylestradiol_107i/Position_provided_by_CMDh/WC500144127.pdf, janvier 2017.
  • [23] Baldo B.A., Fisher M.M. Substituted ammonium ions as allergenic determinants in drug allergy. Nature. 1983;306:262-264.
  • [24] Johansson S.G.O., Florvaag E., Oman H. National pholcodine consumption and the prevalence of IgE-sensitisation; a multicenter study. Allergy. 2010;65:498-502.
  • [25] Florvaag E., Johansson S.G.O., Irgens Å., de Pater G.H. IgE-sensitisation to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market. Allergy. 2011;66:955-960.
  • [26] Johansson S.G.O., Oman H., Nopp A., Florvaag E. Pholcodine caused anaphylaxis in Sweden 30 years ago. Allergy. 2009;64:820-821.
  • [27] ANSM, avril 2011.
  • [28] UpToDate : Drug information: dextromethorphan, date d’accès juillet 2015. https://www.uptodate.com/contents/table-of-contents/drug-information/patient-drug-information, janvier 2017.
  • [29] Korppi M., Laurikainen K., Pietikaenen M., Silvasti M. Antitussives in the treatment of acute transient cough in children. Acta Paediatr Scand. 1991;80:969-971.
  • [30] Paul I.M., Yoder K.E., Crowell K.R. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics. 2004;114:E85-E90.
  • [31] Bhattacharya M., Joshi N., Yadav S. To compare the effect of dextromethorphan, promethazine and placebo on nocturnal cough in children aged 1-12 years with upper respiratory tract infections: a randomized controlled trial. Indian J Pediatr. 2012;80:891-895.
  • [32] Parvez L., Vaidya M., Sakhardande A., Subburaj S., Rajagopalan T.G. Evaluation of antitussive agents in man. Pulm Pharmacol. 1996;9:299-308.
  • [33] Lee P.C.L., Jawad M.S.M., Eccles R. Antitussive efficacy of dextromethorphan in cough associated with acute upper respiratory infection. J Pharm Pharmacol. 2000;52:1137-1142.
  • [34] Pavesi L., Subburaj S., Porter-Shaw K. Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: a meta-analysis. Chest. 2001;120:1121-1128.
  • [35] Eddy N.B. Codeine and its alternates for pain and cough relief. Bull Org Mond Sante. 1969;40:639-719.
  • [36] Lettre H., Albrecht M. Narcotin, Ein Mitosegift. Naturwissenschaften. 1942;12:184-185.
  • [37] Empey DW, Laitinen LA, Young GA, Bye CE, Hughes DT. Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol 1979; 16: 393-7.
  • [38] https://www.drugs.com/cdi/carbetapentane-suspension.html, janvier 2017.
  • [39] Brown C., Fezoui M., Selig W.M., Schwartz C.E., Ellis J.L. Antitussive activity of sigma-1 receptor agonists in the guinea-pig. Br J Pharmacol. 2004;141:233-240. 10.1038/sj.bjp.0705605 (PMC 1574192. PMID 14691051)
  • [40] Arzneistoff- Pro le (in German) 4 (23 ed.). In: Dinnendahl V., Fricke U., eds. Eschborn, Germany: Govi Pharmazeutischer Verlag; 2010. ISBN 978-3-7741-9846-3
  • [41] Stier B.J. Pentoxyverin-Intoxikation über dir Muttermilch bei einem vollgestillten Neugeborenen. DMW. 1988;113:1-4.
  • [42] Bolser D.C. Older-generation antihistamines and cough due to upper airway cough syndrome (UACS) : efficacy and mechanism. Lung. 2008;186:S74-S77.
  • [43] Alison M. Essais thérapeutiques chez les enfants avec un nouveau sirop antitussif à base d’oxomémazine. J Med Lyon 1965; 46: 1683-6.
  • [44] Chang A.B., Peake J., McElrea M.S. Anti-histamines for prolonged non-specific cough in children. Cochrane Database Syst Rev. 2008;2:CD005604. 10.1002/14651858.CD005604.pub3